Immunosuppressive PASylated antibody fragment

About XL-protein

XL-protein is a privately held German biotech specializing in half-life extension technology. Its proprietary PASylation platform offers a biodegradable, polypeptide-based alternative to traditional PEGylation for improving therapeutic proteins. The company operates primarily as a platform and partnering business, out-licensing its technology for preclinical and clinical development across multiple disease areas, as evidenced by its recent license agreement with Grifols.